Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 3;85(7):1381-1394.e6.
doi: 10.1016/j.molcel.2025.02.017. Epub 2025 Mar 17.

Biochemical profiling and structural basis of ADAR1-mediated RNA editing

Affiliations

Biochemical profiling and structural basis of ADAR1-mediated RNA editing

Xiangyu Deng et al. Mol Cell. .

Abstract

ADAR1 regulates RNA-induced immune responses by converting adenosine to inosine in double-stranded RNA. Mutations in ADAR1 are associated with human autoimmune disease, and targeting ADAR1 has been proposed for cancer immunotherapy. However, the molecular mechanisms underlying ADAR1-mediated editing remain unclear. Here, we provide detailed biochemical and structural characterizations of human ADAR1. Our biochemical profiling reveals that ADAR1 editing is both sequence and RNA-duplex-length dependent but can well tolerate mismatches near the editing site. High-resolution ADAR1-RNA complex structures, combined with mutagenesis, elucidate RNA binding, substrate selection, dimerization, and the essential role of RNA-binding domain 3. The ADAR1 structures also help explain the potential defects of disease-associated mutations, where biochemical and RNA sequencing analysis further indicate some of the mutations preferentially impact the editing of RNAs with short duplexes. These findings unveil the molecular basis of ADAR1 editing and provide insights into its immune-regulatory functions and therapeutic potential.

Keywords: ADAR1; Aicardi-Goutières syndrome; RNA editing; cryo-EM.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.W. is a co-founder of Chemical Biology Probes, LLC, and serves as a consultant for CoRegen Inc.

Similar articles

Cited by

References

    1. Nishikura K (2016). A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol 17, 83–96. 10.1038/nrm.2015.4. - DOI - PMC - PubMed
    1. Song B, Shiromoto Y, Minakuchi M, and Nishikura K (2022). The role of RNA editing enzyme ADAR1 in human disease. WIREs RNA 13. 10.1002/wrna.1665. - DOI - PMC - PubMed
    1. Quin J, Sedmík J, Vukić D, Khan A, Keegan LP, and O’Connell MA (2021). ADAR RNA Modifications, the Epitranscriptome and Innate Immunity. Trends Biochem Sci 46, 758–771. 10.1016/j.tibs.2021.02.002. - DOI - PubMed
    1. Rice GI, Kasher PR, Forte GMA, Mannion NM, Greenwood SM, Szynkiewicz M, Dickerson JE, Bhaskar SS, Zampini M, Briggs TA, et al. (2012). Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 44, 1243–1248. 10.1038/ng.2414. - DOI - PMC - PubMed
    1. Tang Q, Rigby RE, Young GR, Hvidt AK, Davis T, Tan TK, Bridgeman A, Townsend AR, Kassiotis G, and Rehwinkel J (2021). Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Immunity 54, 1961–1975.e5. 10.1016/j.immuni.2021.08.011. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources